Refine by
Influenza Vaccination Suppliers & Manufacturers
15 companies found
based inGoyang-si, SOUTH KOREA
Cure Pharmtech is specialized in manufacturing and distributing the highest-quality medicines and medical devices in the world. Recently, South Korea is rapidly becoming an aging society, and a national interest in a healthy life is being promoted. ...
Ingredients: 1.6 mg (900 µg/m²) Thymosin alpha 1 per vial. 1.0 ml of sterile ...
based inGaithersburg, MARYLAND (USA)
We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. We have more than a decade of experience contending with ...
In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant ...
based inGolden, COLORADO (USA)
PharmaJet is a commercial stage MedTech Company with US and International distribution. PharmaJet’s Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. ...
based inMadison, WISCONSIN (USA)
FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. The M2SR Vaccine Platform has the potential to revolutionize the $5 billion annual influenza market, with a clinically-tested vaccine ...
The M2 Deleted Single Replication Live Virus Vaccine (M2SR) offers a potentially differentiating clinical value proposition. FluGen’s flu vaccine candidate works differently, stimulating mucosal, humoral, and cellular immunity, and offering ...
based inBrooklyn, NEW YORK (USA)
Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
BlueWillow’s intranasal vaccine technology has demonstrated safety and immunogenicity in Phase 1 clinical studies using a seasonal influenza vaccine. Several other ongoing BlueWillow programs ...
based inSt-Jean, QUEBEC (CANADA)
We are an innovative pharmaceutical company determined to improve the lige of people with allergy. We have developed our biotechnology with you in mind. How could we turn on sharp insights on allergy and precision medicine into a better life for ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inEdgewater, NEW JERSEY (USA)
Menssana Research is the leading developer of advanced new breath tests for detection of disease. Early detection of diseases can often bring huge benefits: some cancers can be completely eradicated if they are detected early and treated promptly. ...
Seasonal influenza is a common respiratory illness that presents with annual cough and fever epidemics. In the USA, the total economic burden of annual influenza epidemics amounted to $87.1 billion in 2003, arising mainly from outpatient visits, ...
based inAthens, GEORGIA (US) (USA)
Athens Research & Technology Inc. has been purifying human proteins and developing polyclonal antisera to those proteins since 1986. We specialize in highly pure, highly active human proteins. We routinely purify serine proteases, protease ...
IgA is the most abundant immunoglobulin in body fluids and the second most abundant immunoglobulin in plasma, found at a concentration of 0.4 to 2.2 mg/ml. It plays a very important role in the first specific defense against natural infection. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ ...
based inGaithersburg, MARYLAND (USA)
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual ...
Identical vector technology used for AdCOVID (COVID-19), NasoVAX (seasonal influenza) and NasoShield (anthrax) ...
based inMaidenhead, UNITED KINGDOM
As a global leader in influenza protection, CSL Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local ...
As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
A core technology advantage: Live Attenuated Influenza Virus (LAIV) vaccine. BioDiem’s lead asset is the Live Attenuated Influenza Virus (LAIV) vaccine technology. Our LAIV ...